

NOW ENROLLING IN ADJUVANT MELANOMA




PHASE 3 (NCT04410445)

PIVOT-12: Bempegaldesleukin with nivolumab for the adjuvant treatment of melanoma at high risk of recurrence

A Phase 3, randomized, open-label study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy for the adjuvant treatment of patients with completely resected melanoma at high risk of recurrence¹

ENROLL NOW

Scan here to find out more about this clinical study at ClinicalTrials.gov



PRIMARY ENDPOINT

- Recurrence-free survival^b

KEY SECONDARY ENDPOINTS

- Overall survival
- Distant metastasis-free survival
- Safety and tolerability
- Quality of life

Bempegaldesleukin is an investigational CD122-preferential IL-2-pathway agonist²
Nivolumab is a PD-1 blocking antibody³

^aRandomization is stratified by PD-L1 status.

^bAssessed by blinded independent central review.

BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab; PD-1, programmed death-1; PD-L1, programmed death ligand-1.

1. ClinicalTrials.gov. NCT04410445. <https://clinicaltrials.gov/ct2/show/NCT04410445>. Accessed March 29, 2021; 2. Benteibibel SE, et al. *Cancer Discov* 2019;9:711-21; 3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: January 2021).

ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB


NEKTAR

Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE

Scan here to discover more about BEMPEG at Nektar.com



^aNeoadjuvant and adjuvant setting.

BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab; R/R, relapsed/refractory

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2021. All rights reserved.